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Background: Despite the large number of TB 
patients on ART in Ethiopia, their mortality 
remains high. This study reports the effect of TB 
on HIV related mortality and determinants of 
TB/HIV co-infection related mortality.  
Methods: A longitudinal study design was 
employed as part of the Advanced Clinical 
Monitoring of ART (ACM) in Ethiopia. All 
patients started on ART at or after January 1, 
2005 were included. Survival analysis was done 
to compare survival patterns of HIV patients with 
TB against HIV patients without TB. In addition, 
determinants of survival among TB/HIV co-
infected patients were analyzed. Adjusted effects 
of the different factors on time to death were 
generated using Cox-proportional hazards 
regression.  
Results: A total of 3,889 patients were enrolled in 
the ACM study, of which 355 TB cases were 
identified, making the crude prevalence 9% (95% 
CI 8.3 – 10.2). Overall, incidence of TB was 2.2 
(95% CI 1.9-2.4) per 100 person-years. TB was 
highest in the first 2 months and declined with 
time on ART to reach 1 per 100 person years 
after 24 months on ART. TB was significantly 
associated with mortality among HIV patients on 
HAART (AHR 2.0, 95% CI 1.47-2.75). Male 
gender was associated with mortality among 
TB/HIV co-infected patients. 
Conclusion: Tuberculosis plays a key role in 
HIV associated mortality. Targeted interventions 
which can keep patients free of TB in the early 
stages of their treatment are required to reduce 
TB related mortality.  
Key Words: Tuberculosis, Antiretroviral therapy, 
Mortality 
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INTRODUCTION   
 
People living with HIV (PLHIV) and latent 
tuberculosis infection (LTBI) are at much higher 
risk for progressing to active TB disease than 
people with latent TB infection alone. TB remains 
a major illness for people living with HIV/AIDS 
(PLHIV) (1). According to the World Health 
Organization (WHO), of the 9 million new TB 
cases in 2009, more than 1.2 million (13%) were 
PLHIV (2). While PLHIV accounts for only 0.5% 
of the world population, 13% of TB cases across 
the globe are among those with PLHIV. Even 
though there is an improvement in the actual 
number of TB cases, the 2014 WHO global report 
states that out of the 9 million who fell ill with TB 
in 2013, 1.1 million (12.2%) were PLHIV. The 
same report showed that 1.5 million people died 
from TB, out of which 360,000 (24%) were 
PLHIV. Ethiopia is among the sub Saharan 
African countries characterized by a high burden 
of TB as well as HIV (3). 
The WHO recommends that all TB patients 
with HIV should be started on antiretroviral 
therapy (ART) irrespective of their CD4 count(1) 
because ART reduces mortality by 64-95%.(4) 
According to the national annual performance 
report of Ethiopia, 70% of TB patients with HIV 
were put on ART (5), but the mortality in TB/HIV 
co-infected patients remains high even after 
starting ART. Several factors have been identified 
that contribute to the high mortality rate, including 
low baseline CD4 count, having advanced disease 
at start of treatment and not receiving 
treatment(6). Most previous studies addressing TB 
related HIV deaths have focused only on assessing 
the relative contribution of TB to HIV related 
mortality.(7, 8) Also, most studies assessing TB 
burden among those with PLHIV used secondary 
data generated during routine service delivery, 
making disease burden quantification less reliable. 
(7-10). 
In the current study, the aim was to examine 
TB disease burden, the association of TB and HIV 
related mortality, and identify the determinants of 
mortality among those with TB/HIV co-infection 
in seven university teaching hospitals in Ethiopia. 
These hospitals are part of the clinical cohort 
network called the advanced clinical monitoring of 
ART in Ethiopia (ACM) and the data used for the 





Study population: The study population was HIV 
patients on ART who were diagnosed with TB 
disease in the seven teaching and-referral hospitals 
which were included in the ACM project. All 
patients who started ART since 2005 including 
those treated for TB during ART initiation or 
afterwards were included.  
Study design: The study employed a longitudinal 
study design. Study subjects were enrolled using a 
random selection of the advanced clinical 
monitoring of ART clinical cohort (at the 
initiation of the study).  All patients who started 
ART on or after January 1, 2005 were eligible. 
Both ART-experienced and ART-naïve patients 
were enrolled via random selection, after informed 
consent was obtained. Data were collected using 
routine program monitoring tools as well as study 
specific tools. Retrospective data collection 
through chart review was done for all ART-
experienced patients. All data collection was done 
after securing ethical clearance from regulatory 
bodies and all patients who were elgible were 
approached for informed consent and those who 
consented were included into the cohort. Patients 
who were dead at the time of sampling were also 
included if randomly selected.  
Variables and Statistical Analysis: TB diagnosis 
was determined using the Ethiopian national 
guideline where at least 2 sputum smears are 
required for all pulmonary TB suspects and 
relevant tests are done for extra-pulmonary TB 
cases (11). TB disease burden was estimated using 
prevalence estimate as well as incidence rate using 
person-time as a denominator. Incidence rate was 
measured at different time periods after ART 
initiation.  
Data was analyzed using STATA version 12. 
Tables and figures describe the composition and 
structure of participants by key baseline clinical 
and demographic characteristics. Bi-variable 
analysis was performed to evaluate association of 
selected potential factors (i.e., age, gender, WHO 
Stage at baseline, cotrimoxazole and baseline CD4 
count) with mortality. Kaplan-Meier survival 
curves were used to compare survival patterns of 
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those with or after TB and before or without TB 
and statistical significance was tested using log-
rank test. Cox Hazard regression analysis was 
used to generate adjusted effects of the different 
factors at the time of death. To avoid survival bias, 
participants who entered the ACM cohort during 
or after their date of ART start were entered into 
the survival analysis late, with delayed entry (left-
censoring) at their date of ACM enrollment.  
Participants who were terminated from the ACM 
cohort for a reason other than death were recorded 
as having left the risk set (right-censored) on their 
date of termination. 
Factors that were statistically significant at p<0.05 
were considered as potential predictors and were 
included in the multivariable model. The validity 
of the proportional hazards model was examined 
graphically using the Schoenfeld residuals. The 
95% confidence interval for the log hazard ratio 
was used to measure the association of dependent 
and independent variables. In addition to 
identifying the independent predictors, adjusted 
hazard ratios were used to estimate the magnitude 
of association. The value and significance level of 
the intra-site correlation was adjusted for by 
stratification. 
Finally, determinants of survival among patients 
on ART who developed TB after starting ART 









Baseline Characteristics: 3,889 HIV patients 
were analyzed (Fig 1). The median age at 
enrollment was 32 years (IQR 26 – 38). Females 
accounted for 63% of the sample. Most (91%) of 
the patients were above 15 years of age. Median 
follow-up time was 1082 days (IQR 382 – 1951); 
40% of the patients on ART were followed for 
more than four years. The median baseline CD4 
cell count at enrollment was 184/ml (IQR: 86 to 
221). A majority of the sample (63%) had 
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Table 1: Baseline demographic characteristics of participants with TB/HIV co-infection 
 
Characteristics Overall Censored Died 
Number Percent Number Percent Number Percent 
Age        
   <15 359 9% 339 10% 20 5% 
   ≥15 3530 91% 3159 90% 371 95% 
Sex       
   Female 2441 63% 2231 64% 210 54% 
   Male 1448 37% 1267 36% 181 46% 
Base CD4 Count       
   <100 1153 30% 946 27% 207 53% 
   100-350 2561 66% 2395 68% 166 42% 
   ≥350 175 4% 157 4% 18 5% 
Base WHO Stage       
   I –II 1442 37% 1365 39% 77 20% 
   III –IV 2447 63% 2133 61% 314 80% 
CTX       
   No 324 8% 272 8% 52 13% 
   Yes 3565 92% 3226 92% 339 87% 
ART Start Year       
   2005 – 2008 1804 46% 1590 45% 214 55% 
   2009 – 2010 1194 31% 1090 31% 104 27% 
   2011 – 2013 891 23% 818 23% 73 19% 
Tuberculosis       
   No 3534 91% 3198 91% 336 86% 
   Yes 355 9% 300 9% 55 14% 
Total 3889 100% 3498 100% 391 100% 
 
As seen on figure 1 above, The first comparison 
was between the contribution of TB and non-TB 
cases for mortality among HIV patients. The 
second was restricted within TB/HIV cases and it 
was about identifying variables that were 
predictors of death among those cases. 
TB disease burden: Out of the 3,889 patients 
follow during 15,328 Person-years, 355 developed 
TB starting 1st of January 2005, making the crude 
prevalence in this sample 9% (95% CI: 8.3% - 
10.2%). Out of the 355 patients, 24 (6.8%) had 
extra-pulmonary TB. The median time to diagnose 
TB was 204 days (IQR:58-698). The overall 
incidence of TB was 2.19 (95% CI 1.97-2.43) per 
100 person years. The incidence was compared 
based on duration of ART and the findings are 
shown in Table 2 below. 
 
Table 2: Tuberculosis (TB) incidence rates according to duration of antiretroviral therapy (per 100 person 
years). 
ART Duration (month) TB Episodes  Person Year at risk  Rate [95% CI] (per 100 PY) 
0 – 2 93 537 17.3 [14.0 to 2.13] 
2 – 6 80 1087 7.4 [5.84 to 9.16] 
6 – 12 38 1529 2.4 [1.76 to 3.41] 
12 - 24 56 2806 2.0 [1.51 to 2.59] 
> 24 88 10227 0.9 [0.69 to 1.06] 
Overall 355 16185 2.2 [1.97 to 2.43] 
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Incidence was highest in the first two months after 
ART initiation and declined progressively to 1 per 
100 person years after 24 months.  
Most patients who developed TB were young 
adults with 51% being 15- 34 years of age and 
female (54%). Two thirds had either primary or 
secondary education, 43% were married while 
34% were widowed or divorced. Most patients fell 
in the “working” category of functional status 
(60%) with baseline CD4 count of <200 cells/μL 
(75%), and were WHO Stage III or IV (79%), 
received cotrimoxazole (90%) at some point 
during their follow-up, and started with a baseline 
ART regimen containing nevirapine (65%).  
Mortality: A total of 391 deaths were recorded in 
the study cohort resulting in a mortality rate of  
2.6 per 100 person-years (95% CI: 2.3 – 2.8 per 
100). Fifty five (14%) deaths were among those 
who were TB/HIV co-infected. Cotrimoxazole 
was started for 87% of those who died. Of these, 
95% were adults (age≥15), 80% were either WHO 
stage III or IV, and 53% had CD4 cell count <100. 
  
Table 3: Effect of Tuberculosis on Mortality 
 











    
   <15 1    
   ≥15 5.247(2.573 - 10.70) <0.001 9.754 (3.001 - 31.70) <0.001 
Sex     
   Female 1  1  
   Male 1.340(1.085 - 1.655) 0.007 1.276 (1.024 - 1.590) 0.030 
Base CD4 Count     
   <100 1  1  
   100-350 0.456 (0.366 - 0.569) <0.001 0.525 (0.418 - 0.658) <0.001 
   ≥350 0.356 (0.175 - 0.728) 0.005 0.731 (0.351 - 1.525) 0.404 
Base WHO Stage     
   I –II 1  1  
   III –IV 1.618 (1.230 - 2.128) 0.001 1.448 (1.080 - 1.941) 0.013 
CTX     
   No 1  1  
        Yes 0.600 (0.431 - 0.824) 0.002 0.718 (0.508 - 1.013) 0.059 
ART Start Year     
   2005 – 2008 1  1  
   2009 – 2010 1.110 (0.860 - 1.434) 0.422 1.290 (0. 992 - 1.679) 0.057 
   2011 – 2013 1.550 (1.146 - 2.094) 0.004 1.497 (1.427 - 2.728) <0.001 
Tuberculosis     
   No 1  1  
   Yes 2.013 (1.473 - 2.751) <0.001 1.785 (1.289 - 2.473) <0.001 
 * Stratified by facility and functional status. Functional status strongly predicted mortality but couldn’t be 
used in the model since it violated the proportionality assumption. It is for this reason that it was included in 
the stratification to adjust for the main predictor. 
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Association of TB with Mortality: The period of 
follow-up where patients were diagnosed and 
received TB treatment was significantly associated 
with death (crude hazard ratio 2.0 (95% CI 1.47-
2.75)) as compared to the time that all study 
participants were free of TB. After adjusting for 
all available factors, the hazard ratio (HR) was 
1.79 (95% CI 1.29-2.47). 
The Kaplan-Meier failure estimate shown in Fig. 2 
also shows that those with TB have much higher 
probability of death.  
 
Table 4: Baseline demographic characteristics of participants with TB/HIV co-infection 
 
Characteristics Overall Censored Died 
Number Percent Number Percent Number Percent 
Age at ART Start       
<15 17 4.8 15 4.7 2 5.4 
≥15 338 95.1 303 95.3 35 94.5 
Gender        
Female 193 54.4 181 56.9 12 32.4 
Male 162 45.6 137 43.1 25 67.6 
Base CD4 Count       
<50 54 16.2% 47 15.8% 7 18.9% 
50 – 199 196 58.7% 174 58.6% 22 59.5% 
200 – 349 72 21.6% 65 21.9% 7 18.9% 
>=350 12 3.6% 11 3.7% 1 2.7% 
Base WHO Stage       
I or II 73 21% 69 22% 4 11% 
III or IV 279 79% 247 78% 32 89% 
CTX       
Yes 320 90.1% 289 90.9% 31 83.8% 
No 35 9.9% 29 9.1% 6 16.2% 
ART Start Year       
2005 - 2008 238 67.0 214 67.3 24 64.9 
2009 - 2010 96 27.0 85 26.7 11 29.7 
2011 - 2013 21 5.9 19 6.0 2 5.4 
Base Functional Status       
Working 204 59.6% 189 61.6% 15 42.9% 
Ambulatory 113 33.0% 99 32.2% 14 40.0% 
Bedridden  25 7.3% 19 6.2% 6 17.1% 
Facility       
Tikur Anbessa 44 12.4 39 12.3 5 13.5 
ARMY 52 14.6 42 13.2 10 27.0 
Gondar 55 15.5 51 16.0 4 10.8 
Jimma 57 16.1 52 16.4 5 13.5 
Mekelle 42 11.8 37 11.6 5 13.5 
Haramaya 54 15.2 50 15.7 4 10.8 
Hawassa 51 14.4 47 14.8 4 10.8 
Total 355  318 100.0 37 100.0 
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Fig 2: Kaplan-Meier failure curves for time to death by TB status (Log-rank test P<0.0001) 
 
Predictors of survival among those with 
TB/HIV co-infection:  During uni-variable 
analysis, being older age, male, enrolled in the 
early study period, earlier diagnosis of TB after 
enrollment, and being bedridden at enrollment 
were all significantly associated with the 
occurrence of death among HIV patients on ART 
co-infected with TB. However, in the multi-
variable Cox-regression analysis, only gender and 
time to TB diagnosis remained statistically 
significant. 
 
Table 5: Determinants of survival of TB/HIV co-infected patients.  
 
Characteristics Uni-variable analysis Multi-variable analysis 
Hazard ratio(95% CI) P-Value Hazard ratio (95% CI) P-Value 
Age (In Years) 1.033(1.002 - 1.065) 0.04 1.030(0.996 - 1.066) 0.084 
Sex     
  Female 1  1  
  Male 2.622(1.317 - 5.220) 0.006 2.131(1.028 - 4.414) 0.042 
TB Start Year 0.798(0.668 - 0.952) 0.012 1.049(0.878 - 1.253) 0.600 
Time To TB diagnosis 0.993(0.990 - 0.996) 0.000 0.993(0.989 - 0.996) 0.000 
Base CD4 Count 0.998(0.994 - 1.001) 0.208   
Base WHO Stage     
  I –II 1    
  III –IV 1.947(0.687 - 5.516) 0.210   
Base Functional Status 
  
    
  Working 1  1  
  Bedridden/Ambulatory 2.152(1.100 - 4.208) 0.025 1.876(0.933 - 3.771) 0.078 
CTX     
  Yes 1    
  No 1.766(0.737 - 4.235) 0.202   
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Mortality in the study cohort was 2.6 per 100 PY. 
This was more or less similar to other studies from 
Ethiopia (12, 13). Mortality in TB/HIV co-
infected patients in Ethiopia remains high 
compared to those without co-infection (3, 14-16). 
Several factors have been identified to contribute 
to high mortality. However, a particular group of 
TB/HIV co-infected people at risk for mortality 
have not previously been identified. In this study, 
we examined this specific gap in knowledge 
among HIV patients on ART in seven teaching 
university hospitals in Ethiopia. The study found 
TB to be prevalent (8%) in the study population 
while the incidence was 2.2 per 100 person years 
of follow-up. This finding was similar to recent 
studies, but lower than previous estimates that 
were made at the start of ART program (17, 18). 
The incidence of TB was highest in the first two 
months after initiation of ART and declined with 
longer duration on ART. The incidence remained 
high even after 24 months as compared to those 
who were free of HIV. Three hundred ninety one 
patients died during follow-up. The TB-associated 
death was 15%. Tuberculosis was significantly 
associated with mortality among HIV patients on 
HAART compared to the duration when patients 
didn’t have TB: hazard ratio of 2.0 (95% CI 1.47-
2.75) after adjusting for baseline clinical and 
demographic characteristics. Tuberculosis 
associated mortality was twice as much in men as  
in women and higher in the early period after ART 
initiation. 
The prevalence (8%) and incidence (2.2 per 
100 person year) of TB observed in this study is 
comparable with findings by Assefa et al and 
Yirdaw et al (17, 19) but was lower than that 
reported in other settings in Addis Ababa, Gondar 
and Dire Dawa (20-22) with incidence ranging 
from 3.3 to 7.9 per 100 PY. The association of TB 
incidence with duration of ART was also reported 
in other studies (19, 22, 23). Typically most of the 
cases appear in the first six months, decreasing 
thereafter. Some of these declines are associated 
with immune reconstitution inflammatory 
syndrome and in all settings, incidence declined as 
the immune status recovered with ART.  
Association of TB with mortality was 
demonstrated in studies by Setegn et al, Bane et al, 
and Aragie et al. (21, 24, 25). Tuberculosis 
associated mortality typically coincided with peak 
periods of TB diagnosis.  In this current study, we 
showed that most TB related deaths were observed 
in the first six months of ART. In our cohort, the 
important determinants of death in the first six 
months were: having CD4 cell count below 100, 
having other AIDS defining conditions, not 
receiving cotrimoxazole, and being on treatment 
after 2010. These findings are in agreement with 
Setegn et al (24). The fact that mortality increased 
in the later years of treatment where quality of 
care is expected to be better is paradoxical and 
warrants further investigation. 
The determinants of mortality among TB/HIV co-
infected patients on ART in Ethiopia were 
reported in two previous studies. The first was 
carried out in southwestern Ethiopia with an 
unmatched case-control design. Results showed 
that being male, bed ridden and having a cough for 
more than two weeks at enrollment were 
independent predictors of mortality (26). The 
second study was a randomized controlled trial by 
Amogne et al (28); results indicated having lower 
BMI, serum albumin <3 gms/dl and baseline CD4 
count of below 50 cells/μL were determinants of 
mortality. The association of gender, and to some 
extent functional status, found in the current study 
is supported by findings from the first study(27). 
In the Amongne study, all patients were first 
diagnosed as TB and later started on ART at one, 
four and eight week intervals. Hence, a direct 
comparison with our study is not possible. The 
overall mortality was 10% at the end of that study 
(48 weeks) was lower than the mortality in this 
study (15%). Findings of mortality from most 
observational studies carried out in Ethiopia are in 
agreement with the current study with values 
ranging from 15 to 18% (24, 28, 29).  
This current study provides more insight into 
the importance of the first few months after 
starting ART treatment on the quality of life of 
patients with TB/HIV co-infection. This is the 
period with high likelihood of occurrence of TB-
related morbidity and mortality. Investing 
maximum effort at this high risk time ensures 
delivery of high quality TB screening and 
subsequent treatment and support leading to 
improved survival. In addition, particular 
subgroups of PLHIV identified in this study could 
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be used to target service delivery to obtain 
maximum benefit from intervention programs.  
This is one of the few prospective 
longitudinal studies showing occurrence of TB co-
infection with HIV and associated mortality. Even 
though most of our findings were comparable to 
other observational studies based on secondary 
data, this study’s results support findings from 
routine program reports that say what? These can 
be used for planning and direct program 
implementation. This study, however, has some 
important limitations. The diagnosis of TB was 
not confirmed with sputum culture and hence may 
be an underestimation of the true prevalence or 
incidence as sputum AFB has low sensitivity (14). 
The viral load also was not determined which may 
have been used to refine models for predicting 
morbidity and mortality.    
In conclusion, TB was found to be important 
contributor for HIV-associated mortality among 
PLHIV on ART. Targeting interventions in the 
first few months after ART initiation may have a 
greater impact on reducing TB/HIV related 





The findings and conclusions in this report are 
those of the author(s) and do not necessarily 
represent the official position of the Centers for 




The Research has been supported by the 
President’s Emergency Plan for AIDS Relief 
(PEPFAR) through the Centers for Disease 
Control and Prevention (CDC) under the terms of 
Cooperative Agreement with Johns Hopkins 




1. World Health Organisation. Consolidated 
guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection: 
recommendations for a public health approach. 
Geneva, Switzerland2013. 
2. World Health Organisation. Global Tuberculosis 
Control Report 2010. Geneva, Switzerland. 
2010. 
3. World Health Organization. Global Tuberculosis 
Report 2014. 2014. 
4. World Health Organisation. Antiretroviral 
therapy for HIV infection in adults and 
adolescents: recommendations for a public 
health approach– 2010 revision. 2010. 
5. Federal Ministry of Health. Health Sector 
Annual Performance Report. 2014. 
6. Agbor AA, Bigna JJR, Billong SC, Tejiokem 
MC, Ekali GL, Plottel CS, et al. Factors 
Associated with Death during Tuberculosis 
Treatment of Patients Co-Infected with HIV at 
the Yaoundé Central Hospital, Cameroon: An 8-
Year Hospital-Based Retrospective Cohort 
Study (2006–2013). PloS one. 
2014;9(12):e115211. 
7. Pepper DJ, Schomaker M, Wilkinson RJ, de 
Azevedo V, Maartens G. Independent predictors 
of tuberculosis mortality in a high HIV 
prevalence setting: a retrospective cohort study. 
AIDS research and therapy. 2015;12(1):1-9. 
8. Bigna JJR, Noubiap JJN, Agbor AA, Plottel CS, 
Billong SC, Ayong APR, et al. Early Mortality 
during Initial Treatment of Tuberculosis in 
Patients Co-Infected with HIV at the Yaoundé 
Central Hospital, Cameroon: An 8-Year 
Retrospective Cohort Study (2006-2013). PloS 
one. 2015;10(7):e0132394. 
9. Abay SM, Deribe K, Reda AA, Biadgilign S, 
Datiko D, Assefa T, et al. The Effect of Early 
Initiation of Antiretroviral Therapy in TB/HIV 
Coinfected Patients A Systematic Review and 
Meta-Analysis. Journal of the International 
Association of Providers of AIDS Care 
(JIAPAC). 2015:2325957415599210. 
10. Subbarao S, Wilkinson KA, Van Halsema CL, 
Rao SS, Boyles T, Utay NS, et al. Raised 
Venous Lactate and Markers of Intestinal 
Translocation Are Associated With Mortality 
Among In-Patients With HIV-Associated TB in 
Rural South Africa. JAIDS Journal of Acquired 
Immune Deficiency Syndromes. 
2015;70(4):406-13. 
11. Federal Ministry of Health. Guideline for 
clinical and Programatic management of TB, 
TB/HIV and Leprosy in Ethiopia. FIFTH ed. 
Addis Ababa, Ethiopia2013. 
12. Edessa D, Likisa J. A Description of Mortality 
Associated with IPT plus ART Compared to 
ART Alone among HIV-Infected Individuals in 
Addis Ababa, Ethiopia: A Cohort Study. PloS 
one. 2015;10(9):e0137492. 
          Ethiop J Health Sci.                               Vol. 27, Special issue No. 1                      May 2016 
 




13. Damtew B, Mengistie B, Alemayehu T. Survival 
and determinants of mortality in adult HIV/Aids 
patients initiating antiretroviral therapy in 
Somali Region, Eastern Ethiopia. Journal of 
AIDS & Clinical Research. 2014;2014. 
14. Federal Ministry of Health Ethiopian Health and 
Nutrition Research Institute. First Ethiopian 
national population based TB prevalence survey. 
Ethiopia. . 2011. 
15. Zheng Z, Cui Z, Huang M, Pan D. (Effect of 
antiretroviral therapy in reducing deaths among 
patients co-infected with Mycobacterium 
tuberculosis and human immunodeficiency virus 
in Guangxi). Zhonghua liu xing bing xue za zhi= 
Zhonghua liuxingbingxue zazhi. 
2015;36(2):124-7. 
16. Gesesew H, Tsehaineh B, Massa D, Tesfay A, 
Kahsay H, Mwanri L. The role of social 
determinants on tuberculosis/HIV co-infection 
mortality in southwest Ethiopia: a retrospective 
cohort study. BMC research notes. 2016;9(1):1. 
17. Yirdaw KD, Jerene D, Gashu Z, Edginton M, 
Kumar AM, Letamo Y, et al. Beneficial Effect 
of Isoniazid Preventive Therapy and 
Antiretroviral Therapy on the Incidence of 
Tuberculosis in People Living with HIV in 
Ethiopia. PloS one. 2014;9(8):e104557. 
18. Jerene D, Næss A, Lindtjørn B. Antiretroviral 
therapy at a district hospital in Ethiopia prevents 
death and tuberculosis in a cohort of HIV 
patients. AIDS Research and Therapy. 
2006;3(1):10. 
19. Assefa A, Gelaw B, Getnet G, Yitayew G. The 
effect of incident tuberculosis on immunological 
response of HIV patients on highly active anti-
retroviral therapy at the university of Gondar 
hospital, northwest Ethiopia: a retrospective 
follow-up study. BMC infectious diseases. 
2014;14(1):468. 
20. Alene KA, Nega A, Taye BW. Incidence and 
predictors of tuberculosis among adult people 
living with human immunodeficiency virus at 
the University of Gondar Referral Hospital, 
Northwest Ethiopia. BMC infectious diseases. 
2013;13(1):292. 
21. Kassa A, Teka A, Shewaamare A, Jerene D. 
Incidence of tuberculosis and early mortality in a 
large cohort of HIV infected patients receiving 
antiretroviral therapy in a tertiary hospital in 
Addis Ababa, Ethiopia. Transactions of the 
Royal Society of Tropical Medicine and 
Hygiene. 2012;106(6):363-70. 
22. Assefa D, Melaku Z, Gadissa T, Negash A, 
Hinderaker S, Harries A. Intensified tuberculosis 
case finding among people living with the 
human immunodeficiency virus in a hospital 
clinic in Ethiopia (Notes from the field). The 
International Journal of Tuberculosis and Lung 
Disease. 2011;15(3):411-3. 
23. Gupta A, Wood R, Kaplan R, Bekker L-G, 
Lawn SD. Tuberculosis incidence rates during 8 
years of follow-up of an antiretroviral treatment 
cohort in South Africa: comparison with rates in 
the community. PloS one. 2012;7(3):e34156. 
24. Setegn T, Takele A, Gizaw T, Nigatu D, Haile 
D. Predictors of Mortality among Adult 
Antiretroviral Therapy Users in Southeastern 
Ethiopia: Retrospective Cohort Study. AIDS 
research and treatment. 2015;2015. 
25. Bane A, Yohannes A, Fekade D. Morbidity and 
mortality of adult patients with HIV/AIDS at 
Tikur Anbessa Teaching Hospital, Addis Ababa, 
Ethiopia. Ethiopian medical journal. 
2003;41(2):131-40. 
26. Deribe K, Yami A, Deribew A, Mesfin N, 
Colebunders R, Woldie M, et al. Predictors of 
Mortality among Tuberculosis-HIV-Coinfected 
Persons in Southwest Ethiopia A Case–Control 
Study. Journal of the International Association 
of Providers of AIDS Care (JIAPAC). 
2013:2325957413500528. 
27. Wondwosen Amogne GA, Abiy Habtewold, 
Getnet Yimer, Eyasu Makonnen, Alemayhu 
Worku, Anders Sonnerborg, Eleni Aklillu, Lars 
Lindquist. Efficacy and Safety of Antiretroviral 
Therapy Initiated One Week after Tuberculosis 
Therapy in Patients with CD4 Counts < 200 
Cells/μL: TB-HAART Study, a Randomized 
Clinical Trial. PLoS ONE 10(5):e0122587 
doi:101371/journalpone0122587. 2015. 
28. Shaweno D, Worku A. Tuberculosis treatment 
survival of HIV positive TB patients on directly 
observed treatment short-course in Southern 
Ethiopia: A retrospective cohort study. BMC 
research notes. 2012;5(1):682. 
29. Sileshi B, Deyessa N, Girma B, Melese M, 
Suarez P. Predictors of mortality among TB-
HIV Co-infected patients being treated for 
tuberculosis in Northwest Ethiopia: a 
retrospective cohort study. BMC infectious 
diseases. 2013;13(1):297. 
